Insights into the Clinico-Epidemiological Aspects of Non-Epithelial Ovarian Tumor Emphasizing Diagnosis and Tailored Surgical Approach; a Single Institutional Retrospective Study

Abstract

Background: Ovarian cancers account for approximately 27% of all female tumors, with non-epithelial ovarian cell carcinoma being rare at around 10% of overall ovarian cancer cases. The aim of this study is to recognize the prognostic factors Reporting survival outcome in the form of OAS, DFS, and PFS. Aim and Objectives: The aim of the study is: Defining the lines of treatment have been uses and recognize the prognostic factors Reporting survival outcome in the form of OAS, PFS, and DFS. Patients and Methods: This study included fifty-six patients, who had recruited in the period between January 2005 and December 2020 with the following criteria: Proven non-epithelial ovarian carcinoma, all stages, age greater than 18 years. All statistical analyses will be performed using a software tool (SPSS) (statistical package for social sciences) version 26. Quantitative data will be summarized as medians & minimum-maximum values (range) or mean & standard deviation, while qualitative data as percentages. The results will be considered significant if the p-value was < 0.05. Results: all 56 patients (100%) underwent surgery: 96.4% had upfront early debulking, and 3.6% had interval debulking post-neoadjuvant chemotherapy. Fertility Sparing Surgery was performed in 50%, optimal debulking in 41.4%. Surgical debulking left no residual disease in 78.6% (44 patients); 12 patients had residual disease (R1 or R2). Chemotherapy was administered to 55.4% of patients, with 67.7% receiving the BEP regimen and 9 patients receiving other regimens. Pathological responses in 12 patients with residual disease 75% achieved complete response. After a median follow-up of 61 months (20 to 200 months), the study found a median (OAS) of 66 months (22-201 months). The 5-year OAS rate was 94.6% for 53 patients. Median (PFS) was 66 months (15-201 months), with a 5-year PFS rate of 85.7% for 48 patients. Among 44 completely treated patients, (DFS) was 83 months (range: 24-201 months), with a 5-year DFS rate of 93.2% for 41 patients. (Supplementary table is available). Conclusion: According to the data presented in this study, by univariate analysis; performance status, stage, type of surgery, and tumor residual after debulking surgery were significant prognostic factors for survival .